155 related articles for article (PubMed ID: 26712902)
1. Serum neuron-specific enolase level is an independent predictor of overall survival in patients with gastroenteropancreatic neuroendocrine tumors.
van Adrichem RC; Kamp K; Vandamme T; Peeters M; Feelders RA; de Herder WW
Ann Oncol; 2016 Apr; 27(4):746-7. PubMed ID: 26712902
[No Abstract] [Full Text] [Related]
2. Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas.
Pavel ME; Hassler G; Baum U; Hahn EG; Lohmann T; Schuppan D
Clin Endocrinol (Oxf); 2005 Apr; 62(4):434-43. PubMed ID: 15807874
[TBL] [Abstract][Full Text] [Related]
3. Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors.
Chou WC; Chen JS; Hung YS; Hsu JT; Chen TC; Sun CF; Lu CH; Hwang TL
Anticancer Res; 2014 Oct; 34(10):5661-9. PubMed ID: 25275071
[TBL] [Abstract][Full Text] [Related]
4. Hormonal tumor mapping for liver metastases of gastroenteropancreatic neuroendocrine neoplasms: a novel therapeutic strategy.
Maekawa A; Kudo A; Kishino M; Murase Y; Watanabe S; Ishikawa Y; Ueda H; Akahoshi K; Ogawa K; Ono H; Tanaka S; Kinowaki Y; Tanabe M
J Cancer Res Clin Oncol; 2022 Mar; 148(3):697-706. PubMed ID: 33904982
[TBL] [Abstract][Full Text] [Related]
5. The uncovering and characterization of a CCKoma syndrome in enteropancreatic neuroendocrine tumor patients.
Rehfeld JF; Federspiel B; Agersnap M; Knigge U; Bardram L
Scand J Gastroenterol; 2016 Oct; 51(10):1172-8. PubMed ID: 27191542
[TBL] [Abstract][Full Text] [Related]
6. Discussion.
Surgery; 2016 Jan; 159(1):347. PubMed ID: 26456129
[No Abstract] [Full Text] [Related]
7. Are G3 ENETS neuroendocrine neoplasms heterogeneous?
Vélayoudom-Céphise FL; Duvillard P; Foucan L; Hadoux J; Chougnet CN; Leboulleux S; Malka D; Guigay J; Goere D; Debaere T; Caramella C; Schlumberger M; Planchard D; Elias D; Ducreux M; Scoazec JY; Baudin E
Endocr Relat Cancer; 2013 Oct; 20(5):649-57. PubMed ID: 23845449
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life, anxiety, depression and impulsivity in patients with advanced gastroenteropancreatic neuroendocrine tumours.
Lewis AR; Wang X; Magdalani L; D'Arienzo P; Bashir C; Mansoor W; Hubner R; Valle JW; McNamara MG
World J Gastroenterol; 2018 Feb; 24(6):671-679. PubMed ID: 29456406
[TBL] [Abstract][Full Text] [Related]
9. Use of neuron-specific enolase as a serum marker for neuroendocrine neoplasms.
Prinz RA; Marangos PJ
Surgery; 1982 Nov; 92(5):887-9. PubMed ID: 7135210
[No Abstract] [Full Text] [Related]
10. Regular chromogranin A monitoring facilitated the early detection of a gastrointestinal neuroendocrine tumour in a patient with type 1 diabetes.
Herold Z; Uhlyarik A; Herold M; Nagy P; Huszty GD; Rosta K; Doleschall M; Somogyi A
Endokrynol Pol; 2020; 71(5):483-484. PubMed ID: 32856287
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in gastroenteropancreatic neuroendocrine neoplasms].
Chen L; Zhang Y; Chen M; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1002-1008. PubMed ID: 28900990
[TBL] [Abstract][Full Text] [Related]
12. Baseline chromogranin A and its dynamics are prognostic markers in gastroenteropancreatic neuroendocrine tumors.
Rogowski W; Wachuła E; Lewczuk A; Kolasińska-Ćwikła A; Iżycka-Świeszewska E; Sulżyc-Bielicka V; Ćwikła JB
Future Oncol; 2017 May; 13(12):1069-1079. PubMed ID: 28095720
[TBL] [Abstract][Full Text] [Related]
13. Reassessing the grade of gastroenteropancreatic neuroendocrine neoplasms.
Klimstra DS
Endocrine; 2016 Jul; 53(1):4-6. PubMed ID: 27150611
[No Abstract] [Full Text] [Related]
14. Cell-Free DNA and Clinical Characteristics in Patients with Small Intestinal or Pancreatic Neuroendocrine Tumors.
Oversoe SK; Sorensen BS; Tabaksblat EM; Gronbaek H; Kelsen J
Neuroendocrinology; 2022; 112(1):43-50. PubMed ID: 33461190
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic Features of Gastroenteropancreatic Neuroendocrine Tumors: A Single-center Experience.
Akın Telli T; Esin E; Yalçın Ş
Balkan Med J; 2020 Aug; 37(5):281-286. PubMed ID: 32573179
[TBL] [Abstract][Full Text] [Related]
16. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours.
Oberg K
Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S17-25. PubMed ID: 22005113
[No Abstract] [Full Text] [Related]
17. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
[TBL] [Abstract][Full Text] [Related]
18. Gastroenteropancreatic neuroendocrine tumors: current perspectives and future challenges.
Garcia-Carbonero R
Cancer Metastasis Rev; 2014 Mar; 33(1):343-4. PubMed ID: 24357057
[No Abstract] [Full Text] [Related]
19. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.
Yao JC; Pavel M; Phan AT; Kulke MH; Hoosen S; St Peter J; Cherfi A; Öberg KE
J Clin Endocrinol Metab; 2011 Dec; 96(12):3741-9. PubMed ID: 21994954
[TBL] [Abstract][Full Text] [Related]
20. [Controversies of gastroenteropancreatic neuroendocrine tumor pathology diagnosis].
Sasano H; Kasajima A
Nihon Shokakibyo Gakkai Zasshi; 2014 Dec; 111(12):2280-5. PubMed ID: 25482903
[No Abstract] [Full Text] [Related]
[Next] [New Search]
